A descriptive study of plasma cell dyscrasias in Egyptian population.

Autor:	Kassem NM; Clinical Pathology Department, Kasr El-Aini Centre of Clinical Oncology & Nuclear Medicine (NEMROCK), Faculty of Medicine, Cairo University, Cairo, Egypt., El Zawam H; Clinical Oncology Department, Kasr El-Aini Centre of Clinical Oncology & Nuclear Medicine (NEMROCK), Faculty of Medicine, Cairo University, Cairo, Egypt., Kassem HA; Clinical Pathology Department, Kasr El-Aini Centre of Clinical Oncology & Nuclear Medicine (NEMROCK), Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: heba.kasem@hotmail.com., El Nahas T; Clinical Oncology Department, Kasr El-Aini Centre of Clinical Oncology & Nuclear Medicine (NEMROCK), Faculty of Medicine, Cairo University, Cairo, Egypt., El Husseiny NM; Clinical Hematology Department, Faculty of Medicine, Cairo University, Cairo, Egypt., El Azeeim HA; Clinical Oncology Department, Kasr El-Aini Centre of Clinical Oncology & Nuclear Medicine (NEMROCK), Faculty of Medicine, Cairo University, Cairo, Egypt; Cairo Cure Center, Cairo, Egypt.
Jazyk:	angličtina
Zdroj:	Journal of the Egyptian National Cancer Institute [J Egypt Natl Canc Inst] 2014 Jun; Vol. 26 (2), pp. 67-71. Date of Electronic Publication: 2013 Dec 17.
DOI:	10.1016/j.jnci.2013.09.002
Abstrakt:	Background: Plasma cell dyscrasias (PCDs) refer to a spectrum of disorders characterized by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow and, sometimes, tissue deposition of monoclonal immunoglobulins or their components. These disorders include multiple myeloma (MM) and Waldenström's macroglobulinemia, as well as rare conditions such as light-chain deposition disease (LCDD) and heavy-chain diseases (HCDs). The worldwide annual incidence of MM is estimated at 86,000, which is approximately 0.8% of all new cancer cases. Purpose: Our retrospective study aims to highlight the immunologic and epidemiological features of PCDs mainly MM in Egyptian patients and compare our results with those of other populations. Methods: Two hundred seventeen Egyptian patients with PCD were enrolled in the study. Serum, urine protein electrophoresis and immunofixation were used to demonstrate M protein. Results: One hundred thirty-eight patients (63.6%) had IgG monoclonal band, 38 patients (17.5%) had IgA, 12 patients (5.5%) had Waldenström's macroglobulinemia (IgM monoclonal band) and 29 patients (13.4%) were light chain myeloma. One hundred fifty-one (70%) were Kappa chain positive and 66 patients (30%) were lumbda positive. Conventional cytogenetics was available for 40 patients; of them12 patients (30%) showed 13q-. Mean OS was 37.5months (1-84months). Survival analysis was statistically insignificant according to age, sex and ISS or type of treatment (P value>0.05). Conclusion: Long term follow up is required to further define the role of different therapeutic lines of treatment including ASCT in the various stages of PCD based on OS data. (Copyright © 2013. Production and hosting by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu